

19 August 2022

SourceBio International plc
(‘SourceBio’, the ‘Company’ or the ‘Group’)

Notice of Half Year Results

and

Investor presentation

SourceBio International plc (AIM: SBI), a leading international provider of integrated state-of-the-art laboratory services, announces that its unaudited half year results for the six months ended 30 June 2022 are expected to be released on 8 September 2022.

Investor Presentation

Jay LeCoque, Executive Chairman, and Tony Ratcliffe, Chief Financial Officer, will provide a live presentation on the Half Year Results via the Investor Meet Company platform on the following day, 9th September 2022, at 9:30am BST.

The presentation is open to all existing and potential shareholders. Questions can be submitted pre-event via your Investor Meet Company dashboard up until 9:00am the day before the meeting or at any time during the live presentation.

Investors can sign up to Investor Meet Company for free and add to meet SourceBio International plc via:

<https://www.investormeetcompany.com/sourcebio-international-plc/register-investor>

Investors who already follow SourceBio International plc on the Investor Meet Company platform will automatically be invited.

Contacts:

SourceBio International plc

Jay LeCoque, Executive Chairman
Tony Ratcliffe, Chief Financial Officer

www.sourcebiointernational.com

Via Walbrook PR

Liberum (Nominated Advisor and Broker)

Richard Lindley / William Hall / Miquela Bezuidenhout

Tel: 020 3100 2000

Walbrook PR Limited

Paul McManus / Sam Allen

Tel: 020 7933 8780 or sourcebio@walbrookpr.com

Mob: 07980 541 893 / 07502 558 258

About SourceBio International plc www.sourcebiointernational.com

SourceBio is a leading international provider of integrated state-of-the-art laboratory services with clients in the pharmaceutical, healthcare, clinical, drug development and life sciences research industries, with a focus on improving patient diagnosis, management and care. Group revenues are derived from four business units:

●	Healthcare Diagnostics - Histopathology cancer screening, including Digital Pathology and clinical diagnostic services for the NHS and private healthcare providers across the UK
●	Genomics - DNA sequencing services and Precision Medicine offering for pharmaceutical and biotechnology industries, academia, contract research organisations (CROs) and other research groups in the UK, Europe and North America
●	Stability Storage Controlled environmental storage services and laboratory equipment validation services for pharmaceutical industry in the UK, Ireland and North America

- | | |
|---|--|
| ● | Infectious Disease Testing - A range of COVID-19 testing services for commercial enterprises, private healthcare groups and the NHS, including PCR testing under ISO 15189 accreditation. |
|---|--|

More details on Group operations can be found here: www.sourcebioscience.com

SourceBio International plc (SBI) is listed on the AIM market of the London Stock Exchange.